Medivir, a research-based pharmaceutical company with focus on oncology, has resolved on a private placement of B-shares which provides Medivir with approximately 155 MSEK in issue proceeds before transaction costs. The subscription price of 39 SEK was set following an accelerated bookbuilding process.
Carnegie Investment Bank AB (publ) acted as Global Coordinator and Joint Bookrunner and Kempen & Co N.V. acted as Joint Bookrunner in the transaction. Baker McKenzie has acted as legal advisor to the Joint Bookrunners. The Baker McKenzie team was led by partner Joakim Falkner with support from Ian Gulam in Stockholm and Roger James in London.